Helix Labs raises $130M to accelerate biotech-computing platform for drug discovery

Tech · 5 min read

Helix Labs announced a $130 million Series D led by Sequoia and launched a next-generation compute platform designed to accelerate simulations and AI model training for molecular design. The platform bundles curated datasets, high-throughput compute, and domain-specific modeling tools.

The company emphasizes end-to-end reproducibility and partner integrations with CROs and academic labs. Helix Labs aims to shorten early discovery timelines by enabling rapid iteration on candidate molecules and in-silico assays.

Funds will be invested in data-curation efforts, expanding GPU and specialized accelerator capacity, and regulatory compliance for partnerships in therapeutics. Helix says several pharmaceutical partners are in paid pilots.

Biotech observers note computational platforms are key to lowering costs in early R&D. However, translation to clinical success remains a long road; Helix’s platform must demonstrate tangible time-to-hit and cost-per-hit improvements to justify large-scale adoption.